摘要
目的对不同级别的SHG-44与U251胶质瘤细胞株放射抵抗性差异进行比较,探索放射抵抗性与APEX1 mRNA表达及细胞周期分布的关系。方法采用平板克隆形成实验法检测SHG-44细胞株与U251细胞株之间放射抵抗性的差别;采用RT-PCR技术检测已知的胶质瘤放射抵抗因子APEX1mRNA的表达情况;流式细胞术检测两种细胞细胞周期的分布情况;直线相关分析分析细胞放射抵抗性与APEX1 mRNA的表达情况及细胞周期分布的关系。结果与WHOⅣ级的U251相比,WHOⅡ～Ⅲ级的SHG-44的放射抵抗性较高(SF2_(U251)=0.58±0.02,SF2_(SHG-44)=0.70±0.15,t=3.19,P<0.05),但其APEX1 mRNA表达要低(1.17±0.04 vs.0.70±0.18,t=19.92,P<0.05),G_1期SHG-44比例高于U251(60.13±3.26 vs.51.72±5.14,t=2.51,P<0.05),S期SHG-44低于U251(18.57±0.64 vs.28.80±2.96,t=5.09,P<0.05),G_2期两者差异无统计学意义(17.63±3.91 vs.21.78±4.81,t=1.25,P>0.05),G_1期比例与SF2存在相关性(r=0.735,P<0.05)。结论胶质瘤的放射抵抗性与病理级别可能呈负相关,不同类型胶质瘤的放射抵抗机制可能存在差异,APEX1并不是SHG-44细胞放射抵抗性增高的决定因素,G_1期阻滞可能是SHG-44细胞放射抵抗性增高的原因之一。
Objective To explore the radioresistance difference between SHG-44 and U251 cell line,investigate the correlation among radioresistance, APEX1 mRNA expression and cell
cycle distribution.Methods Colony formation assay was performed to determine the dioresistance difference, APEX1 mRNA expression was determined by RT-PCR,cell cycle
distribution was investigated using flow cytometry, their correlation were analyzed by linear
correlation. Results Compared with U251（pathological grade： WHO Ⅳ）,SHG-44（pathological grade： WHO Ⅱ-Ⅲ） was higher radioresistant（SF2U251=0.58±0.02,SF2SHG-44=0.70±0.15,t=3.19,P〈0.05）,but its APEX1 mRNA expression was lower（1.17±0.04 vs.0.70±0.18,t=19.92,P〈0.05）,its G1 phase proportion was increased（60.13±3.26 vs. 51.72±5.14,t=2.51,P〈0.05）,S phase proportion was decreased（18.57±0.64 vs. 28.80±2.96,t=5.09,P〈0.05）,and there is no significant difference in G2 phase between U251 and SHG-44（17.63±3.91 vs. 21.78±4.81,t=1.25,P〉0.05）,G1 phase arrest was correlated to radioresistance（r=0.735,P〈.05）.Conclusion
Pathological grade and radioresistance may be negatively correlated in glioma,there may be
different radioresistance mechanisms in different types of gliomas, APEX1 is not correlated with radioresistance in glioma SHG-44,but G1 phase may be correlated with radioresistance in glioma SHG-44.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2013年第5期425-429,共5页
Cancer Research on Prevention and Treatment
